Teladoc Health

TDOC · NYSE

$6.21+$0.48 (+8.38%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $5.73

TDOC analyst rating

HoldConsensus of 14 analysts over the last 12 months. 36% rate it a buy.

Strong buy0
Buy5
Hold9
Underperform0
Sell0

12-month price target · 21 analysts

Average $7.79 (+25.5% upside)

Low: $5.55
Now: $6.21
High: $11.02

Upgrades and downgrades

The latest rating actions, newest first

TDOC analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Citigroup	Aug 3, 2026	Maintains	Neutral	$11.00 → $7.50	44%
Canaccord Genuity	Jul 30, 2026	Maintains	Buy	$11.00 → $10.00	43%
Evercore ISI Group	Jul 30, 2026	Maintains	In-Line	$10.00 → $7.50	60%
Canaccord Genuity	Jul 21, 2026	Maintains	Buy	$10.00 → $11.00	43%
B of A Securities	Jul 7, 2026	Maintains	Buy	$9.00 → $10.50	58%
Citigroup	May 5, 2026	Maintains	Neutral	$6.00 → $7.00	44%
Evercore ISI Group	Apr 8, 2026	Maintains	In-Line	$5.00 → $6.00	60%
Barclays	Mar 26, 2026	Maintains	Equal-Weight	$8.50 → $7.00	53%
JP Morgan	Mar 13, 2026	Maintains	Neutral	$9.00 → $7.00	54%
B of A Securities	Mar 10, 2026	Maintains	Buy	$7.00 → $8.25	58%

The case for and against

Updated Aug 18, 2026

Bull case

Teladoc Health is in a precarious position as they navigate a transition from a stable, subscription-based business model to a more volatile, visit-based one, causing uncertainty and a deceleration in revenue growth. However, their ability to deliver whole-person care through their virtual platform gives them a unique advantage and potential for long-term growth. Their success will depend on continued expansion into virtual care and the ability to stabilize revenue and improve profitability.

Bear case

Teladoc Health is facing multiple challenges, including a reliance on their Integrated Care segment for the majority of their revenues, which may be negatively impacted by expected membership declines due to changes in health plan customer enrollment and the expiration of ACA subsidies. The transition to a broader commercial model for their BetterHelp segment could also lead to uncertainty and potential margin pressures. Additionally, the company's focus on AI investments and their lack of pricing power may limit their ability to drive long-term growth and profitability. These factors, combined with potential competitive pressures and the need for significant sales and marketing spend, lead to a negative outlook on Teladoc Health's stock.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.